Cite
Development of a recombinant human IL-15·sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model.
MLA
Zhao, Meiqi, et al. “Development of a Recombinant Human IL-15·sIL-15Rα/Fc Superagonist with Improved Half-Life and Its Antitumor Activity Alone or in Combination with PD-1 Blockade in Mouse Model.” Biomedicine & Pharmacotherapy, vol. 112, Apr. 2019, p. 108677. EBSCOhost, https://doi.org/10.1016/j.biopha.2019.108677.
APA
Zhao, M., Luo, M., Xie, Y., Jiang, H., Cagliero, C., Li, N., Ye, H., Wu, M., Hao, S., Sun, T., Yang, H., Zhang, M., Lin, T., Lu, H., & Zhu, J. (2019). Development of a recombinant human IL-15·sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model. Biomedicine & Pharmacotherapy, 112, 108677. https://doi.org/10.1016/j.biopha.2019.108677
Chicago
Zhao, Meiqi, Manyu Luo, Yueqing Xie, Hua Jiang, Cedric Cagliero, Ninghuan Li, Hao Ye, et al. 2019. “Development of a Recombinant Human IL-15·sIL-15Rα/Fc Superagonist with Improved Half-Life and Its Antitumor Activity Alone or in Combination with PD-1 Blockade in Mouse Model.” Biomedicine & Pharmacotherapy 112 (April): 108677. doi:10.1016/j.biopha.2019.108677.